Over the last decade, EBRP has made remarkable strides, including helping to accelerate the first two EB treatments FDA approved in 2023. 

​Since our founding, we have funded 140 research projects laser-focused on bringing life-saving therapies and cures to the EB community. Our work has transformed the clinical trial landscape from just 2 clinical trials in EB to over 50 today, an over 20x increase.

​Research highlights

"Adapting the iPS Cell-Based Therapy for RDEB to an Automated Platform to Facilitate Clinical Translation"

​"Suppressing the Itch of Dystrophic Epidermolysis Bullosa"​

"Development of a Novel Ophthalmic Solution to Treat Ocular Manifestations of RDEB"

2024

18 PROJECTS APPROVED
​$5.6M AWARDED

VIEW PROJECTS

2023

18 PROJECTS APPROVED
​$5.9M AWARDED
​

VIEW PROJECTS

2022

19 PROJECTS APPROVED
​$6.6M AWARDED
​

VIEW PROJECTS

2021

13 PROJECTS APPROVED
$5.2M AWARDED

VIEW PROJECTS

---

2019

​21 PROJECTS APPROVED
$7.5M AWARDED

view projects

2020

17 PROJECTS APPROVED
$7.2M AWARDED

view projects

---

2018

17 PROJECTS APPROVED
$11M AWARDED

view projects

21 INSTITUTIONS, ONE FOCUS: CURING EB
​Collaboration is central to our model. The EB Clinical Research Consortium (EBCRC) allows each research team to benefit from the others, accelerating progress to heal EB.

Our Collaborations

DRIVING RESULTS FOR PATIENTS.
We find the most promising research projects to fund. But we don't just sign a check and hope for the best. Our innovative Venture Into Cures system ensures maximum impact for the EB community.

Our model

---